Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   41209   clinical trials with a EudraCT protocol, of which   6750   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).


    Phase 1 trials conducted solely in adults and that are not part of an agreed PIP are not public in the EU CTR (refer to European Guidance 2008/C 168/02   Art. 3 par. 2 and   Commission Guideline 2012/C 302/03,   Art. 5) .
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2013-004468-69
    Sponsor's Protocol Code Number:TV1106-IMM-20001
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Prematurely Ended
    Date on which this record was first entered in the EudraCT database:2014-11-03
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2013-004468-69
    A.3Full title of the trial
    A Phase 2, Randomized, Open-Label, Safety and Dose-Finding Study Comparing
    3 Different Doses of Weekly TV-1106 and Daily Recombinant Human Growth Hormone
    (Genotropin®) Therapy in Treatment-Naive, Pre-Pubertal, Growth Hormone-Deficient
    Children
    Estudio en fase 2, aleatorizado y abierto sobre la seguridad y para determinación de la dosis, que compara el tratamiento con una de tres dosis distintas de TV-1106 administrado semanalmente con el tratamiento diario mediante hormona de crecimiento humana recombinante (Genotropin®) en niños y niñas prepuberales con déficit de hormona del crecimiento no tratados previamente.
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A clinical study in children with Growth Hormone Deficiency for dose-finding and assessment of safety of TV-1106 (experimental drug).
    Ensayo clínico en niños con déficit de la hormona del crecimiento para fijar la dosis y determinar la seguridad del fármaco experimental TV-1106
    A.4.1Sponsor's protocol code numberTV1106-IMM-20001
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorTeva Pharmaceutical Industries, Ltd.
    B.1.3.4CountryIsrael
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportTeva Pharmaceutical Industries, Ltd.
    B.4.2CountryIsrael
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationOlga Vargas Gasa
    B.5.2Functional name of contact pointClinical trial information desk
    B.5.3 Address:
    B.5.3.1Street AddressArenys,39-Oficina
    B.5.3.2Town/ cityBarcelona
    B.5.3.3Post code08035
    B.5.3.4CountrySpain
    B.5.4Telephone number+34935504072
    B.5.6E-mailolga.ovginvest@gmail.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameAlbutropin
    D.3.2Product code TV1106
    D.3.4Pharmaceutical form Powder for solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPSubcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNAlbutropin
    D.3.9.2Current sponsor codeTV1106
    D.3.9.3Other descriptive namehuman Serum Albumin (HSA) fused to somatropin
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number25
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameAlbutropin
    D.3.2Product code TV-1106
    D.3.4Pharmaceutical form Powder for solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPSubcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNAlbutropin
    D.3.9.2Current sponsor codeTV-1106
    D.3.9.3Other descriptive nameHuman Serum Albumin (HSA) fused to somatropin
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number50
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 3
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Genotropin
    D.2.1.1.2Name of the Marketing Authorisation holderPfizer Limited
    D.2.1.2Country which granted the Marketing AuthorisationUnited Kingdom
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameRecombinant Human Gowth Hormone
    D.3.2Product code n/a
    D.3.4Pharmaceutical form Powder and solvent for solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPSubcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNsomatropin
    D.3.9.1CAS number 12629-01-5
    D.3.9.2Current sponsor coden/a
    D.3.9.3Other descriptive nameSOMATROPIN
    D.3.9.4EV Substance CodeSUB10584MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number5.3
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Growth hormone deficiency
    Déficit de hormona del crecimiento
    E.1.1.1Medical condition in easily understood language
    Growth hormone deficiency (GHD) is a medical condition, caused by
    problems arising in the pituitary gland, in which the body does not
    produce enough growth hormone (GH).
    E.1.1.2Therapeutic area Diseases [C] - Hormonal diseases [C19]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 17.1
    E.1.2Level PT
    E.1.2Classification code 10056438
    E.1.2Term Growth hormone deficiency
    E.1.2System Organ Class 10014698 - Endocrine disorders
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The primary objective of this study is to determine the safety and tolerability of 3 different weekly doses of TV-1106 and a daily dose of Genotropin® in paediatric patients.
    El objetivo principal de este estudio es determinar la seguridad y la tolerabilidad de tres dosis diferentes de TV-1106 administrado semanalmente y de una dosis diaria de Genotropin® en pacientes pediátricos.
    E.2.2Secondary objectives of the trial
    The secondary objectives of the study is to evaluate the efficacy of 3 different weekly doses of TV-1106 and a daily dose of Genotropin® as demonstrated by height velocity (HV), height velocity standard deviation score (HV-SDS), and height standard deviation score (H-SDS).
    El objetivo secundario del estudio es evaluar la eficacia de tres dosis diferentes de TV 1106 administrado semanalmente y de una dosis diaria de Genotropin®, medida por la velocidad de crecimiento (VC), la puntuación de la desviación estándar de la velocidad de crecimiento (PDE-VC) y la puntuación de la desviación estándar de la estatura (PDE-E).
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    a. Pre-pubertal (Tanner 1/1/1) boys ? 3 years to ? 11 years and pre-pubertal girls ? 3 years to ? 10 years at time of informed consent signing with isolated idiopathic growth hormone (GH) insufficiency, GH insufficiency as part of multiple pituitary hormone deficiencies, or organic GH insufficiency (e.g., due to pituitary tumor, pituitary or brain surgery, intracranial radiation therapy);
    b. Diagnosis confirmed by 2 different GH provocation tests for GH secretion (e.g., insulin tolerance test and arginine test) as described in consensus guidelines (GH Research Society 2000, Gharib et al 2003, Rose 2007). Historical medical documents of GH provocation tests (including the insulin tolerance test (ITT) and arginine test; cortisol levels measured at 0 and 90 minutes during the ITT test) can be used for study eligibility. The peak GH concentration must be below 10 ng/mL for inclusion in the study;
    c. All patients must have at least one cranial imaging study [magnetic resonance imaging (MRI) or computed tomography (CT)] prior to randomization:
    - To exclude intracranial causes of GHD in patients without a history of pituitary tumor [obtained within 6 months prior to informed consent signing (Visit 1-SCR)], or
    - Patients with a previously treated pituitary tumor must have no tumor progression for at least the past year [obtained within 3 months prior to informed consent signing (Visit 1), compared with a previous MRI or CT performed at least 12 months earlier].
    If not performed within these specified time frames prior to informed consent signing, may be performed as part of the screening procedures.
    d. H-SDS ? -2.0; using CDC 2000 growth reference standards (Kuczmarski et al., 2002).
    e. HV-SDS <0 (minimum time between 2 standard height measurements should be at least 6 months prior to study entry; one of the measurements can be taken during the screening visit. The data should be determined from medical records and include dates and method of height measurement); using Swiss growth reference standards (Prader et al., 1989).
    f. IGF-I SDS < -1.0;
    g. Body Mass Index (BMI) ? 95th percentile of BMI for CA and sex according to the 2000 Centers for Disease Control (CDC) standards;
    h. Written Informed Consent of the parent(s) or legal guardian of the patient and a verbal or written assent from the patients, where possible;
    i. Parent or legal guardian who is capable and willing to administer the study drug.
    a. Niños prepuberales (Tanner 1/1/1) de ? 3 años a ? 11 años y niñas prepuberales de ? 3 años a ? 10 años en el momento de firmar el consentimiento informado, que sufran insuficiencia idiopática aislada de hormona del crecimiento (HC), insuficiencia de HC como parte de múltiples deficiencias hormonales hipofisarias o insuficiencia orgánica de HC (por ejemplo, debida a un tumor hipofisario, a cirugía del cerebro o de la hipófisis o a radioterapia intracraneal)
    b. Diagnóstico confirmado por 2 pruebas diferentes de estimulación con HC para la secreción de HC (por ejemplo, la prueba de tolerancia a la insulina y la prueba de la arginina), tal como se describe en las guías de consenso (GH Research Society 2000, Gharib et al 2003, Rose 2007). Pueden utilizarse documentos médicos anteriores de pruebas de estimulación con HC (incluyendo la prueba de tolerancia a la insulina [PTI] y la prueba de la arginina; los niveles de cortisol se miden en los minutos 0 y 90 durante la prueba PTI) para determinar la elegibilidad para el estudio. La concentración máxima de HC debe ser inferior a 10 ng/ml para la inclusión en el estudio
    c. Todos los pacientes deben disponer como mínimo de un estudio de imagen craneal (resonancia magnética [RM] o tomografía axial computarizada [TAC]) antes de la aleatorización:
    ? Para excluir causas intracraneales del DHC en pacientes sin antecedentes de tumor hipofisario (las imágenes deben haberse obtenido en los 6 meses anteriores a la firma del consentimiento informado [visita 1, selección]), o
    ? Los pacientes con un tumor hipofisario tratado previamente no deben presentar evolución del tumor durante al menos el último año (las imágenes deben haberse obtenido en los 3 meses anteriores a la firma del consentimiento informado [visita 1] y compararse con una RM o TAC anterior realizada 12 meses antes como mínimo)
    Si el estudio de imagen craneal no se ha realizado dentro de los plazos indicados antes de firmar el consentimiento informado, puede realizarse como parte de los procedimientos de selección.
    d. PDE-E ? ?2,0, según los patrones de referencia de crecimiento CDC 2000 (Kuczmarski et al., 2002)
    e. PDE-VC < 0 (el tiempo mínimo entre 2 mediciones estándar de la estatura debe ser al menos 6 meses anterior a la entrada en el estudio, y una de las medidas puede tomarse durante la visita de selección; Los datos deben determinarse a partir de la historia clínica y deben incluir las fechas y el método de medición de la estatura); deben utilizarse los patrones de referencia de crecimiento suizos (Prader et al., 1989)
    f. PDE del FCI-I < ?1,0
    g. Índice de masa corporal (IMC) ? percentil 95.o del IMC según EC y sexo, de acuerdo con los patrones de los Centers for Disease Control (CDC) del año 2000
    h. Consentimiento informado por escrito del padre/la madre o el tutor legal del paciente, más, siempre que sea posible, un asentimiento verbal o escrito de los pacientes.
    i. El padre/la madre o el tutor legal son capaces de administrar el fármaco del estudio y están dispuestos a hacerlo
    E.4Principal exclusion criteria
    a. Any clinically significant abnormality as determined by the investigator, that is likely to affect growth or ability to grow (e.g., chronic diseases such as renal insufficiency or advanced diseases such as acquired immunodeficiency syndrome [AIDS] or tuberculosis; intracranial, cranio-spinal, or spinal cord irradiation; malnutrition);
    b. Contraindications to rhGH treatment;
    c. History of or currently active malignancy, including malignant intra-cranial tumors;
    d. Children with new diagnosis of pituitary/hypothalamic tumor or of intracranial tumor as confirmed by MRI or CT within 12 months prior to baseline (Visit 2-BL);
    e. Bone age, determined by the standard method (Greulich and Pyle, 1959), greater than CA or greater than 9 for girls or greater than 10 for boys within 3 months of screening. If not done within 3 months of screening, may be performed as part of screening procedures;
    f. Patients with known diagnosis of diabetes or pre-diabetes (impaired fasting glucose) as defined in the American Diabetes Association position statement (American Diabetes Association, 2013);
    g. Clinically-determined chromosomal abnormalities and ?medical syndromes? (e.g., Noonan syndrome, Turner?s syndrome, Prader-Willi syndrome, Russell-Silver syndrome, short stature homeobox [SHOX], mutations/deletions); Chromosomal testing may be ordered at the PI's discretion if needed.
    h. Skeletal dysplasias;
    i. Children born small for gestational age (SGA, defined as birth weight and/or birth length < -2 standard deviations [SDs] for gestational age);
    j. Evidence of closed epiphyses;
    k. Growth altering medications such as anabolic steroids or methylphenidate, except for pituitary replacement hormone therapy (thyroxine, hydrocortisone, desmopressin);
    l. Children requiring glucocorticoid therapy (e.g., for asthma) in excess of 400 ?g/day of inhaled budesonide (or equivalents) inhaled for longer than 1 month during the last calendar year;
    m. Poorly controlled or uncontrolled pituitary hormone insufficiencies (i.e., stable therapy less than 6 months for thyroid replacement and 3 months for other hormone replacements);
    n. Hypersensitivity to the study medication components;
    o. Participation in another investigational agent trial within 30 days prior to screening;
    p. Other causes of short stature, such as celiac disease, malabsorption syndromes, untreated hypothyroidism, rickets, psychosocial dwarfism;
    q. Any medical condition as judged by the investigator to interfere with patient participation or the objectives of the study;
    r. Patients with signs and/or symptoms of increased intracranial pressure at screening.
    a. Cualquier anomalía clínicamente significativa, según determine el investigador, que sea probable que afecte al crecimiento o a la capacidad de crecer (por ejemplo, enfermedades crónicas como insuficiencia renal, o enfermedades avanzadas como síndrome de inmunodeficiencia adquirida [SIDA] o tuberculosis; irradiación intracraneal, craneoespinal o espinal; malnutrición)
    b. Contraindicaciones al tratamiento con HChr
    c. Neoplasia maligna activa o antecedentes de neoplasias malignas, incluyendo tumores intracraneales malignos
    d. Niños y niñas con un nuevo diagnóstico de tumor hipofisario/hipotalámico o de tumor intracraneal, confirmado por RM o TAC en los 12 meses anteriores al momento basal (visita 2 BL)
    e. Edad ósea, determinada por el método estándar (Greulich and Pyle, 1959), superior a la EC o superior a 9 en niñas o a 10 en niños en los 3 meses anteriores a la selección. Si esta determinación no se ha realizado en los 3 meses anteriores a la selección, puede efectuarse como parte de los procedimientos de selección
    f. Pacientes con diagnóstico de diabetes o prediabetes (glucemia en ayunas alterada), según la definición de la American Diabetes Association (American Diabetes Association, 2013)
    g. Anomalías cromosómicas y ?síndromes médicos? (por ejemplo, síndrome de Noonan, síndrome de Turner, síndrome de Prader-Willi, síndrome de Russell-Silver, homeosecuencia de la baja estatura [SHOX], mutaciones/deleciones) que se hayan determinado clínicamente; si es necesario, pueden solicitarse pruebas cromosómicas a discreción del IP
    h. Displasias esqueléticas
    i. Niños o niñas con un tamaño al nacer pequeño para la edad gestacional (PEG, que se define como un peso al nacer y/o una longitud al nacer < ?2 desviaciones estándar [DE] para la edad gestacional)
    j. Evidencia de epífisis cerradas
    k. Medicamentos que alteran el crecimiento, como esteroides anabolizantes o metilfenidato, excepto en el caso de tratamiento restitutivo de hormonas hipofisarias (tiroxina, hidrocortisona, desmopresina)
    l. Niños y niñas que requieren tratamiento con glucocorticoides (por ejemplo, para el asma) de más de 400 ?g/día de budesonida inhalada (o equivalentes), que se haya tomado durante más de 1 mes durante el último año natural
    m. Insuficiencias hormonales hipofisarias mal controladas o no controladas (es decir, tratamiento estable de menos de 6 meses para la restitución tiroidea y de menos de 3 meses para otras restituciones hormonales)
    n. Hipersensibilidad a los componentes de la medicación del estudio
    o. Participación en otro ensayo sobre un fármaco en investigación en los 30 días anteriores a la selección
    p. Otras causas de baja estatura, como celiaquía, síndromes de malabsorción, hipotiroidismo no tratado, raquitismo o enanismo psicosocial
    q. Cualquier patología médica que, a juicio del investigador, interfiera con la participación del paciente o los objetivos del estudio
    r. Pacientes con signos y/o síntomas de aumento de la presión intracraneal en el momento de la selección
    E.5 End points
    E.5.1Primary end point(s)
    The primary efficacy variable and endpoint for this study is
    HV after 6 months of treatment.
    La variable y el criterio de valoración principales de la eficacia de este estudio es la VC al cabo de 6 meses de tratamiento.
    E.5.1.1Timepoint(s) of evaluation of this end point
    after 6 months of treatment.
    Después 6 meses de tratamiento.
    E.5.2Secondary end point(s)
    The secondary efficacy variables and endpoints for this study are as follows:
    - HV at 12 months of treatment;
    -HV-SDS at 6 months and at 12 months of treatment. HV-SDS will be calculated using Swiss growth reference standards (Prader et al, 1989, see Appendix E);
    - Change in H-SDS from baseline to 6 months and 12 months of treatment. HV-SDS will be calculated using the CDC 2000 growth reference standards (Kuczmarski et al, 2002, Appendix F).
    -VC a los 12 meses de tratamiento
    -PDE-VC a los 6 meses y a los 12 meses de tratamiento; la PDE-VC se calculará mediante los patrones de referencia de crecimiento suizos (Prader et al., 1989).
    -Cambio en la PDE-E desde el momento basal hasta los 6 y 12 meses de tratamiento. La PDE-E se calculará mediante los patrones de referencia de crecimiento CDC 2000 (Kuczmarski et al., 2002)
    E.5.2.1Timepoint(s) of evaluation of this end point
    - HV at 12 months of treatment;
    - HV-SDS at 6 months and at 12 months of treatment;
    - Change in H-SDS from baseline to 6 months and 12 months of treatment.
    - VC a los 12 meses de tratamiento
    - PDE-VC a los 6 meses y a los 12 meses de tratamiento
    - Cambio en la PDE-E desde el momento basal hasta los 6 y 12 meses de tratamiento
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response Yes
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) Yes
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial4
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned1
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA20
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Belarus
    Bulgaria
    Czech Republic
    Georgia
    Greece
    Hungary
    Israel
    Poland
    Romania
    Russian Federation
    Serbia
    Slovenia
    Spain
    Turkey
    Ukraine
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    Trial will be concluded after a follow up approximately 3 weeks after the last dose of the study drug.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years3
    E.8.9.1In the Member State concerned months0
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years3
    E.8.9.2In all countries concerned by the trial months0
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 Yes
    F.1.1Number of subjects for this age range: 60
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) Yes
    F.1.1.5.1Number of subjects for this age range: 60
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) No
    F.1.3Elderly (>=65 years) No
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception No
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally Yes
    F.3.3.6.1Details of subjects incapable of giving consent
    Patients are between 3-12 years old and therefore not able to give legal consent. Parents or legal guardian will sign the informed consent. Patients will sign as well in case they are able to read, understand and
    sign.
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state3
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 30
    F.4.2.2In the whole clinical trial 60
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Patient will be referred back to his physician to evaluate need for ongoing treatment with growth hormone. Another commercially available growth hormone may be prescribed at the physician?s recommendation.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2015-01-22
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2014-12-01
    P. End of Trial
    P.End of Trial StatusPrematurely Ended
    For support, visit the EMA Service Desk , log in using your EMA account and open a ticket specifying "EU CTR" in your request.
    If you do not have an account, please visit the EMA Account management page page click on "Create an EMA account" and follow the instructions.
    The status of studies in GB is no longer updated from 1.1.2021
    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2021 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA